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Abstract
Summary We demonstrated that osteoporosis is associated
with a preferential type II muscle fiber atrophy, which
correlates with bone mineral density and reduced levels of
Akt, a major regulator of muscle mass. In osteoarthritis,
muscle atrophy is of lower extent and related to disease
duration and severity.
Introduction Osteoarthritis (OA) and osteoporosis (OP) are
associated with loss of muscle bulk and power. In these
diseases, morphological studies on muscle tissue are lack-
ing, and the underlying mechanisms of muscle atrophy are
not known. The aim of our study was to evaluate the OP- or
OA-related muscle atrophy and its correlation with severity
of disease. Muscle levels of Akt protein, a component of
IGF-1/PI3K/Akt pathway, the main regulator of muscle
mass, have been determined.
Methods We performed muscle biopsy in 15 women with
OP and in 15 women with OA (age range, 60–85 years).
Muscle fibers were counted, measured, and classified by
ATPase reaction. By statistical analysis, fiber-type atrophy
was correlated with bone mineral density (BMD) in the OP
group and with Harris Hip Score (HHS) and disease duration
in the OA group. Akt protein levels were evaluated by West-
ern blot analysis.
Results Our findings revealed in OP a preferential type II
fiber atrophy that inversely correlated with patients’ BMD.
In OA, muscle atrophy was of lower extent, homogeneous
among fiber types and related to disease duration and HHS.
Moreover, in OP muscle, the Akt level was significantly
reduced as compared to OA muscles.
Conclusions This study shows that in OP, there is a prefer-
ential and diffuse type II fiber atrophy, proportional to the
degree of bone loss, whereas in OA, muscle atrophy is
connected to the functional impairment caused by the dis-
ease. A reduction of Akt seems to be one of the mechanisms
involved in OP-related muscle atrophy.
Keywords Akt . Muscle atrophy . Osteoarthritis .
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Introduction
Osteoporosis, osteoarthritis, and sarcopenia are the most
frequent musculo-skeletal disorders affecting older persons.
Osteoporosis (OP) is a widespread disorder affecting
millions of individuals of all ethnic backgrounds worldwide,
particularly among older women [1]. OP is a complex
multifactorial disease characterized by reduced bone mass
and microarchitectural deterioration of bone tissue, with a
consequent increase of fracture risk [2]. Based on a 3-year
multicenter survey, the senior author has estimated in Italy
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an incidence of 410,000 hip, humeral, wrist, ankle, and
vertebral fragility fractures. These results confirm that OP
is a leading cause of morbidity in the Italian population and
a challenging health problem to be addressed by implement-
ing appropriate preventive strategies [3]. There is a rapidly
expanding amount of information, based on laboratory stud-
ies, indicating that OP is likely to be caused by complex
interactions among local and systemic regulators of bone
cell function [2]. Osteoarthritis (OA) is a chronic–degener-
ative joint disease defined by pain, joint stiffness, and a
progressive loss of function with considerable impact on
the quality of life. OA is one the most frequent causes of
disability among the aged, and it is more prevalent in elderly
women than in men [4].
OP and OA have been reported in strong association with
sarcopenia [5, 6], a term used to indicate the progressive
reduction in muscle mass and strength or function that
affects older people [7]. Sarcopenia is considered to be
one of the major factors responsible for functional limita-
tions and motor dependency in elderly persons [5]. In age-
related muscle atrophy, a decrease in both muscle fiber size
and number, and a preferential loss of type II fibers, have
been reported [8].
Declines in the circulating levels of specific hormones
(e.g., estrogens, testosterone, growth hormone, insulin-like
growth factor-1 (IGF-1)) have been demonstrated to be
associated with sarcopenia and seem to have an important
role in its pathogenesis. Similarly, in osteoporotic women,
post-menopausal declines in serum hormone levels contrib-
ute to increased osteoclastogenesis and bone loss [9, 10].
One of the most important mediators of muscle and bone
growth is IGF-1, a peptide hormone, structurally similar to
insulin, that exerts its effects through a specific receptor,
IGF-1R, that is one of the most potent natural activators of
the PI(3)/Akt signaling pathway [10]. Akt acts through
different downstream mediators all leading to stimulation
of cell growth and proliferation [11].
Sarcopenia in OP and OA is usually evaluated by indirect
measures, such as dual-energy X-ray absorptiometry
(DXA), bioelectrical impedance, anthropometry, urinary
creatine–creatinine ratio, CT or MRI cross-sectional muscle
scan, body mass index (BMI), and muscle strength and
physical performance tests, whereas direct morphological
studies on muscle tissue are lacking [7, 12].
The aim of this study was to analyze, by morpho-
metric analysis, the presence and the degree of muscle
atrophy in female patients with OP or OA and evaluate
if a correlation between this atrophy and patients’
age, BMI, stage of disease, bone mineral density
(BMD) was present. Moreover, we have investigated
if the Akt pathway is involved in OP-related muscle




We performed a vastus lateralis muscle biopsy in 15 women
with OP undergoing surgery for fragility hip fracture and in
15 age-matched women (age range, 60–85 years) undergo-
ing arthroplasty for hip osteoarthritis. The patients were
informed about the experimental procedures and signed an
informed consent form before participating in the study. The
study was approved by the Ethical Committee of Tor Ver-
gata University Hospital (protocol number 120/06).
Bone mineral density evaluation
DXA was performed with a Lunar iDXA apparatus (GE
Healthcare, Madison, WI, USA). Lumbar spine (L1–L4)
and femoral (neck and total) scans were performed, and
BMD was analyzed as previously described [13]. Dual-
energy X-ray absorptiometry measures BMD (in grams per
square centimeter) with a coefficient of variation of 0.7 %.
In the OA group, all measurements were performed on the
non-dominant side, while participants lay supine on an
examination table with their limbs abducted away from the
trunk. For the OP group, BMD was measured on the limb
opposite the fracture side. Results are expressed as absolute
values and as T-scores. Women with fragility hip fracture, a
T-score ≤−2.5 SD, and a negative radiographic framework
for hip OA were included in the OP group (BMD femoral
neck range values, 0.454–0.645 g/cm2). Women with a
positive radiogram for hip OA and T-score ≥−2.5 SD were
included in the OA group (BMD femoral neck range
values, 0.845–1.197 g/cm2). Patients with neuromuscular
diseases, diabetes mellitus, HBV, HCV, HIV infections,
smoke or alcohol dependence, or treated with corticoste-
roids or hormonal drugs for a period exceeding 1 month
were excluded from the study. The Harris Hip Score
(HHS) of the affected side was calculated in all OA
patients. HHS is a scale used to evaluate the degree of
pain and functional impairment of the hip joint; it is based
on a total of 100 (possible) points, and higher scores
indicate better hip function [14].
No significant differences were found in BMI values be-
tween the two groups (BMI mean values: OP, 24.4 kg/m2;
OA, 23.8 kg/m2).
Morphometric analysis
Muscle biopsies were taken from the upper portion of the
vastus lateralis during open surgery for hip arthroplasty or
for synthesis with intramedullary nail. This muscle was
chosen because it is hardly influenced by the fracture event,
and it is a good indicator of systemic muscle atrophy related
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to the disease. Muscle specimens were frozen in melting
isopentane and stored at −80 ° until use. Histological eval-
uations were performed on transverse cryostat sections
(7 μm thick) stained with hematoxylin–eosin, Gomori tri-
chrome, ATPase after preincubation at pH 4.2, NADH-
dehydrogenase, and cytochrome c oxidase. The presence
of other myopathies was ruled out by routine histopatholog-
ical survey. Morphometric analysis was performed on serial
transverse cryostat sections stained with ATPase after pre-
incubation at pH 4.2 as previously described [15]. Morpho-
metric data were obtained by using a semiautomatic image
analysis system (QWin Standard V3, Leica, Cambridge,
UK). A minimum of 200 muscle fibers per biopsy have
been evaluated, comparing type I and type II fibers for
relative prevalence, minimum transverse diameter, and
cross-sectional area. We accounted as atrophic fibers with
a diameter lower than 30 μm, which is the minimum value
of the normal range for women [16, 17].
Immunoblotting
To evaluate whether Akt is involved in OP-related muscle
atrophy, muscle homogenates of six OP patients and six age-
matched OA control biopsies were immunoblotted, as recent-
ly detailed [18]. In brief, 20 μg of protein was loaded into 4–
20 % NuPAGE gels (Invitrogen, Carlsbad, CA) and electro-
phoretically separated. After electrophoresis, samples were
transferred to a nitrocellulose membrane. To prevent non-
specific binding of the antibodies, the nitrocellulose mem-
branes were blocked in 3 % BSA. They were then incubated
overnight at 4°C with a primary antibody against Akt (Cell
Signaling Technology, Boston, MA), diluted 1:50. Blots were
developed using the Enhanced Chemiluminescence Western
Blotting Substrate (Pierce, Rockford, Illinois) in combination
with horseradish peroxidase-conjugated secondary antibody
(DAKO, Milano, Italy). Protein loading was evaluated by the
actin band, and quantification of the immunoreactivity was
performed by densitometric analysis using NIH Image J 1.310
software.
Statistical analysis
Standard statistical procedures were used to calculate means
and standard deviation (SD) of age, BMI, and BMD. The
statistical significance of the differences in prevalence of
fiber type, predominance of fiber atrophy, and Akt muscle
protein levels, between the two groups of patients, was
determined by Student’s t test. Correlation analysis was
performed using the Pearson product–moment correlation
test; p values lower than 0.05 were considered significant; a
negative sign indicates an inverse correlation.
Results
Prevalence of fiber types
Routine histological stainings showed absence of inflamma-
tion, necrosis, regeneration, fibrosis, or other changes in all
biopsies, excluding the presence of other muscular diseases.
Morphometric analysis performed on ATPase reaction at
pH 4.2 did not show any significant difference in fiber type
distribution between the two groups of patients. The per-
centage of type I fibers in OP and OAwas 54.72 and 54.81,
respectively; the percentage of type II fibers was 45.28 and
45.19, respectively. The absence of a variability in fiber-type
prevalence between OP and OA indicates that any differ-
ence in muscle fiber diameter between the two groups of
patients cannot be ascribed to variation in fiber-type
composition.
Fiber diameter and incidence of fiber atrophy
The ATPase reaction showed a diffuse atrophy of type II
fibers in the OP muscle biopsies (Fig. 1a). The morphomet-
ric analysis of muscle fibers in OP patients showed mean
values for minimum transverse diameter ranging between
31.25 and 42.83 μm for type I fibers and between 26.45 and
39.12 μm for type II fibers; mean values for area were
ranging from 972.1 to 2,680.2 μm2 for type I fibers and
between 651.0 and 1,720.3 μm2 for type II fibers. In the OA
group, the mean fiber diameter was between 35.2 and
50.34 μm for type I fiber and between 33.49 and
53.69 μm for type II fibers; the mean fiber area was between
1,532.8 and 2,792.5 μm2 for type I fiber and between
1,644.0 and 2,857.8 μm2 for type II fibers.
The analysis of the mega-histogram showed that fiber
diameters in the OP group had a higher degree of deviation
from the normal distribution toward the atrophic range,
compared to OA. This deviation was slight for type I fibers
and very prominent for type II fibers (Fig. 1b).
In the OA group, 8.25% of type I fibers and 12.5 % of type
II fibers were atrophic. In the OP group, atrophy was more
prominent and involved preferentially type II fibers: in fact,
11.67 % of type I fibers and 36.86 % of type II fibers were
atrophic. In both groups, type II fiber atrophy was significant-
ly more frequent than type I fiber (p value <0.01), with a
threefold ratio in OP and only a 1.5-fold ratio in OA.
On the basis of these raw data, in order to take into
account the fact that large deviations from the normal range
are more important than small ones, we calculated the atro-
phy factor (AF) for the different fiber types in both groups,
as previously described [15–17]. This analysis showed that
the AF for type I fiber was 155 in OP and 110 in OA
(normal threshold value, 100). The AF for type II fibers
was 451 in OP and 185 in OA (normal threshold value,
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200), thus confirming that type II atrophy is a prominent
feature in OP only.
Correlation analysis
To verify if there was a correlation between percentage of
muscle atrophy found in these two groups of patients and
severity of disease, we performed the Pearson product–
moment correlation test. The statistical analysis showed that
in OP, the percentage of type II fiber atrophy correlated with
neck and total femoral BMD values (correlation coefficient
r0−0.6 and p value <0.05) (Fig. 1c), but not with type I
fiber atrophy, patient’s age, and BMI.
In OA, type I and type II fiber atrophy were highly
correlated with each other (correlation coefficient r0
0.875, p value <0.0001) and with disease duration (cor-
relation coefficient r00.664 and 0.655, respectively;
p value <0.01), and inversely correlated with HHS
(correlation coefficient r0−0.730 and −0.562, respec-
tively; p value <0.05). No correlation was found
between either type I and type II fiber atrophy and
patient’s age or BMI.
Immunoblotting
Considering that muscle homogenates include both normal
and atrophic fibers, as well as both type I and type II fibers, we
selected OP muscle biopsies showing the higher degrees of
type II fiber atrophy, and OA biopsies with the lowest degrees
of atrophy, in order to confidently relate the Akt reduction to
the preferential type II muscle atrophy found in OP.
To determine whether changes in Akt protein level contrib-
ute to the type II fiber atrophy present in OP, we performed
immunoblot analysis on six OP muscle biopsies and six OA
age-matched control biopsies. In OP muscle, total Akt was
decreased 2.5-fold as compared to OA (p<0.05) (Fig. 2).
Discussion
In this study, we analyzed and compared morphological mus-
cle features associated with OP and OA, the twomost frequent
skeletal diseases affecting older persons. Those disorders have
been both associated to the presence of sarcopenia that, in
turn, increases the risk of disability and bone fragility. Our
results showed different patterns of muscular involvement in
OA and OP. In the latter, muscle atrophy is prominent and
affects preferentially type II muscle fibers, with less or no
impact observed in type I fibers. This atrophy correlates with
BMD, suggesting that disease severity has a central role in the
pathogenesis of OP-related muscle atrophy. In OA, muscle
atrophy is much less pronounced compared to OP, and is
homogeneous among both fiber types. In OA, muscle atrophy
is connected with disease duration and patient’s HHS, repre-
senting the degree of pain and functional impairment caused
by the disease.
Fig. 1 Analysis of muscle fiber atrophy. a In osteoporosis, vastus
lateralis muscle biopsy reacted for ATPase pH 4.2 shows a preferential
type II muscle fiber (light fibers) atrophy. b Mega-histogram compar-
ing fiber diameter distribution in OP and OA. Type II fibers in the OP
group have a higher degree of deviation from the normal distribution
toward the atrophic range. c Linear regression graph showing in OP an
inverse correlation between type II fiber atrophy and BMD
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A single study has previously reported a higher prevalence
of atrophy among type II fibers in osteoporotic patients with
low levels of 25-hydroxyvitamin D, although a correlation
with the degree of OP was not tested. Unfortunately, many of
the biopsies used in that study showed alterations suggestive
of concomitant muscular diseases [19].
The OP-related muscle atrophy bears some similarity
with other systemic conditions such as cachexia, diabetes,
and steroid myopathy, in which a preferential and diffuse
involvement of type II fibers has been described [20–22]. In
those chronic conditions, a decrease in the levels of specific
hormones causes a reduced activation of the IGF-1/PI3K/
Akt pathway, the major regulator of postnatal growth of
muscle, leading to impaired glucose intake, an altered mus-
cle metabolism, and muscle atrophy. IGF-1 exerts its effects
through a specific receptor, IGF-1R, that is one of the most
potent natural activators of the PI(3)/Akt signaling pathway.
Akt, through different downstream mediators, promotes
protein synthesis and retards protein degradation by regu-
lating the expression of various atrogenes [10, 11]. In addi-
tion, IGF-1 is able to counteract the effects of myostatin, a
member of the TGFβ family involved in muscle atrophy
[23]. The hypothesis that Akt is implicated also in OP-
related muscle atrophy is supported by our Western blot
analysis, showing a significant reduction of Akt levels in
OP atrophic muscles, compared to OA muscles. In fact,
similarly to other metabolic myopathies, the decline of
specific hormones, including IGF-1, occurring in OP might
downregulate IGF-1/PI3K/Akt activity, leading to muscle at-
rophy. Moreover, since IGF-1/PI3K/Akt controls glucose up-
take in skeletal muscle [10], its downregulation could affect
mainly glycolytic fibers (type II), whereas oxidative fibers
(type I) tend to be more resistant to atrophy, because of their
capacity of utilizing other substrates than glucose to produce
energy. Downstream mediators of Akt, such as mTOR,
p70S6K, FoxO1, GSK3b, are to be studied to better clarify
the IGF-1/PI3K/Akt role in OP-related muscle atrophy.
An involvement of IGF-1/PI3K/Akt in OP, rather than in
OA patients, could explain the muscle morphological differ-
ences found in those diseases. In fact, in OP patients, type II
fiber atrophy is more prominent and selective as compared to
OA and is related to severity of bone mass reduction. All
patients in the OP group were examined for the first time on
admission because of the hip fracture and did not refer any
important limitation in their physical daily activity. This leads
to the hypothesis that OP muscle atrophy is independent from
muscle disuse. The reduced bone density occurring in OP
patients is due mainly to a decrease of circulating hormones,
and according to the reduced Akt levels found in OP, we
believe that OP muscle atrophy has the same pathogenesis.
Conversely, our OA patients complained of a decline in
their physical activity due to pain and functional impairment
in the affected joint for some time before surgery, suggesting
that their muscle atrophy could be mainly due to disuse. In
confirmation of that, OA-related muscle atrophy was of
lower extent, more homogeneous among fiber types (even
if type II fibers are more liable to size variations), and
correlated to the HHS and disease duration. Whether other
factors, such as myostatin, systemic or local inflammatory
mediators, cytokines, or inflammatory transcription factors,
can contribute to the muscle atrophy present in OP and OA
should be matter for further investigation.
Our morphological study on vastus lateralis muscles
failed to show, in both groups of patients, denervation
features such as type grouping or angulated fibers, reported
to be present in distal senescent muscle [24] but not in
proximal muscle [25]. The lack of correlation between both
OP and OA type II fiber atrophy and patients’ age could be
explained by the fact that the primary causes of muscle
atrophy in these two diseases (hormonal decline and Akt
decrease for OP, and disuse due to pain and joint disability
for OA) prevail over the effects of physiological muscle
aging, as previously described in OA [25].
In summary, muscle atrophy in OP and OA is not related
to age and may have different etiologies, the IGF-1/Akt
pathway being involved only in OP-related muscle atrophy.
Bone mineral density correlated with, and could be used as a
marker of, muscle atrophy in osteoporotic patients, whereas
disease duration and severity of pain could predict muscle
impairment in OA. Further studies need to be performed to
Fig. 2 Akt is decreased in OP muscle fibers. Representative immuno-
blot and densitometric analysis show that in OP muscle, Akt is reduced
2.5-fold as compared to OA. The actin bands indicate protein loading
in each sample
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better understand the underlying mechanisms of OP- and
OA-related muscle atrophy and to ascertain whether similar
changes occur also in males.
According to our results, physical activity should be
recommended to reduce and prevent OA-related muscle
atrophy. Physical activity could be useful also in OP to
mitigate muscle atrophy and bone loss due to hormonal
decline in the attempt to reduce fracture risk and disability,
as previously described [2, 13]. Moreover, pharmacological
enhancement of the IGF-1/Akt pathway, to increase protein
synthesis and diminish muscle atrophy, might provide a
novel therapeutic opportunity in OP-related sarcopenia.
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